Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Position Lifted by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lifted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 7.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 142,300 shares of the company’s stock after purchasing an additional 9,300 shares during the quarter. Ensign Peak Advisors Inc owned 0.27% of Janux Therapeutics worth $7,619,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Russell Investments Group Ltd. grew its stake in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after purchasing an additional 442 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after purchasing an additional 599 shares in the last quarter. Kennedy Capital Management LLC grew its stake in shares of Janux Therapeutics by 7.9% in the fourth quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company’s stock worth $681,000 after purchasing an additional 928 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Janux Therapeutics by 5.8% in the fourth quarter. MetLife Investment Management LLC now owns 17,298 shares of the company’s stock worth $926,000 after purchasing an additional 949 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Janux Therapeutics by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock worth $596,000 after purchasing an additional 1,095 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Analyst Ratings Changes

JANX has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a research note on Monday, March 3rd. Wedbush reaffirmed an “outperform” rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, Scotiabank decreased their target price on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $95.25.

Janux Therapeutics Stock Down 2.8%

Shares of NASDAQ JANX opened at $25.33 on Wednesday. Janux Therapeutics, Inc. has a 12 month low of $22.52 and a 12 month high of $71.71. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -21.65 and a beta of 3.24. The business has a fifty day simple moving average of $29.06 and a 200-day simple moving average of $41.29.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insider Buying and Selling

In other Janux Therapeutics news, Director Ra Capital Management, L.P. acquired 341,742 shares of Janux Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The stock was purchased at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. The trade was a 3.67% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $2,630,912.17. This represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,001 shares of company stock valued at $313,964. Corporate insiders own 8.10% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.